Status:
UNKNOWN
Evaluation of Janus Kinase_3 in Juvenile Onset Systemic Lupus Erythematosus
Lead Sponsor:
Assiut University
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
7-16 years
Brief Summary
One of the best understood mechanisms by which cytokines activate signals, thus eliciting specific responses in target cells, involves enzymes such as Janus kinases (JAKs) and transcriptional factors ...
Detailed Description
Investigators will assess the relationship between the expression of Janus\_kinase 3 and the clinical and laboratory parameters of disease activity . Disease activity will be assessed through the Syst...
Eligibility Criteria
Inclusion
- Age younger than 16 years.
- Active disease stage
- Patients with biopsy proven lupus nephritis according to ISN/RPS classification criteria of lupus nephritis
Exclusion
- Lupus patients in remission.
- Lupus patients with end stage renal disease.
- Lupus patients with secondary thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS).
- patients with moderate or severe infection
Key Trial Info
Start Date :
July 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 15 2022
Estimated Enrollment :
67 Patients enrolled
Trial Details
Trial ID
NCT04293510
Start Date
July 15 2020
End Date
July 15 2022
Last Update
March 4 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.